634586-40-6
Chemical Structure
PDC31
Synonym(s): THG113.31; ILGHXDYK
- CAS No.: 634586-40-6
- Formula:C45H71N13O13
- Molecular Weight:1002.12
InChIKey: IVQBXMPXSLAIFC-OSMHAOILSA-N
SMILES: OC(C=C1)=CC=C1C[C@H](C(N[C@@H](C(O)=O)CCCCN)=O)NC([C@@H](CC(O)=O)NC([C@@H](CCCNC(N)=O)NC([C@H](NC(CNC([C@@H](CC(C)C)NC([C@H](N)[C@H](C)CC)=O)=O)=O)CC2=CN=CN2)=O)=O)=O
Biological Activity: PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca2+-dependent large-conductance K+-channel in human myometrial cells[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PDC31 | 98.67% | PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca2+-dependent large-conductance K+-channel in human myometrial cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.75
HY-P10908H-20 -
Similarity Score 0.74
HY-P11046IIIM1 -
Similarity Score 0.73
HY-P11649NYLTHRQ -
Similarity Score 0.72
HY-P5408OVA-Q4H7 Peptide -
Similarity Score 0.72
HY-P0197Neurokinin A -
Similarity Score 0.71
HY-P0216A 779 -
Similarity Score 0.71
HY-P10491MAGE A4 (230-239) -
Similarity Score 0.71
HY-P10264MAGE-3 peptide -
Similarity Score 0.71
HY-P1760Allatostatin IV -
Explore the MedChemAI to find more analogs
References
- [1]. Sharif NA, et al. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility. Br J Pharmacol. 2019 Apr;176(8):1059-1078. [Content Brief]
- [2]. Doheny HC, et al. THG113.31, a specific PGF2alpha receptor antagonist, induces human myometrial relaxation and BKCa channel activation. Reprod Biol Endocrinol. 2007 Mar 16;5:10. [Content Brief]
